Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albuvirtide in HIV-1 patients with end-stage renal disease on hemodialysis
ChiCTR2200058014Phase 4Not yet recruiting
- Sponsor
- Chongqing Public Health Medical Treatment Center
- Start
- Mar 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of albuvirtide in Human immunodeficiency virus infection type 1, sponsored by Chongqing Public Health Medical Treatment Center. Primary endpoints: Peak serum concentration of albuvirtide and Incidence of grade 3 or greater adverse events related to therapeutic agents. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
albuvirtide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on ChiCTR2200058014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058014.